Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage
biopharmaceutical company announced today the commencement of patient
dosing with Supinoxin
TM (RX-5902) in a Phase I clinical trial
designed to study...